Detalhe da pesquisa
1.
Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
Clin Infect Dis
; 2024 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38462673
2.
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
N Engl J Med
; 384(18): 1705-1718, 2021 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33951360
3.
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials.
Am J Respir Crit Care Med
; 207(10): 1376-1382, 2023 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36790881
4.
Factors associated with prevalent Mycobacterium tuberculosis infection and disease among adolescents and adults exposed to rifampin-resistant tuberculosis in the household.
PLoS One
; 18(3): e0283290, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36930628
5.
Liquid mycobacterial culture outcomes after different sputum collection techniques before and during treatment.
Tuberculosis (Edinb)
; 116: 17-21, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31153513
6.
C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial.
PLoS One
; 13(9): e0204554, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30248152